JP2022539157A5 - - Google Patents
Info
- Publication number
- JP2022539157A5 JP2022539157A5 JP2021577431A JP2021577431A JP2022539157A5 JP 2022539157 A5 JP2022539157 A5 JP 2022539157A5 JP 2021577431 A JP2021577431 A JP 2021577431A JP 2021577431 A JP2021577431 A JP 2021577431A JP 2022539157 A5 JP2022539157 A5 JP 2022539157A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- sequence
- cancer
- cells
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183318.5 | 2019-06-28 | ||
| EP19183318 | 2019-06-28 | ||
| EP20170163 | 2020-04-17 | ||
| EP20170163.8 | 2020-04-17 | ||
| PCT/GB2020/051557 WO2020260897A1 (en) | 2019-06-28 | 2020-06-26 | Novel cancer antigens and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022539157A JP2022539157A (ja) | 2022-09-07 |
| JP2022539157A5 true JP2022539157A5 (cg-RX-API-DMAC7.html) | 2023-07-05 |
| JP7887250B2 JP7887250B2 (ja) | 2026-07-09 |
Family
ID=71266763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577431A Active JP7887250B2 (ja) | 2019-06-28 | 2020-06-26 | 新規な癌抗原及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220220175A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3990006A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7887250B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220029561A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114341169B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020302285A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026364A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3141553A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289200A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021015765A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020260897A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119978090A (zh) | 2018-10-19 | 2025-05-13 | 弗朗西斯·克里克研究所有限公司 | 新的癌抗原和方法 |
| EP3994156A1 (en) | 2019-07-05 | 2022-05-11 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| EP4136096A1 (en) * | 2020-04-17 | 2023-02-22 | The Francis Crick Institute Limited | Antigen pool |
| EP4136097A1 (en) * | 2020-04-17 | 2023-02-22 | The Francis Crick Institute Limited | Fusion proteins of ctl antigens for treating melanoma |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| JP2003304877A (ja) * | 2002-04-15 | 2003-10-28 | Keio Gijuku | ヒト色素細胞特異分子 |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| EP2402447A1 (en) | 2005-03-30 | 2012-01-04 | Viroxis | Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| AT502292B1 (de) | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| WO2007109583A2 (en) | 2006-03-17 | 2007-09-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| WO2009039244A2 (en) | 2007-09-18 | 2009-03-26 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| MA43477A1 (fr) * | 2016-04-21 | 2019-05-31 | Immatics Biotechnologies Gmbh | Immunothérapie contre le mélanome et d'autres cancers |
| CN113329761A (zh) * | 2018-09-04 | 2021-08-31 | 特雷斯生物有限公司 | 肽疫苗 |
| CN119978090A (zh) | 2018-10-19 | 2025-05-13 | 弗朗西斯·克里克研究所有限公司 | 新的癌抗原和方法 |
-
2020
- 2020-06-26 WO PCT/GB2020/051557 patent/WO2020260897A1/en not_active Ceased
- 2020-06-26 EP EP20735233.7A patent/EP3990006A1/en active Pending
- 2020-06-26 BR BR112021026364A patent/BR112021026364A2/pt not_active IP Right Cessation
- 2020-06-26 CN CN202080047510.8A patent/CN114341169B/zh active Active
- 2020-06-26 JP JP2021577431A patent/JP7887250B2/ja active Active
- 2020-06-26 MX MX2021015765A patent/MX2021015765A/es unknown
- 2020-06-26 KR KR1020217039990A patent/KR20220029561A/ko not_active Ceased
- 2020-06-26 CA CA3141553A patent/CA3141553A1/en active Pending
- 2020-06-26 AU AU2020302285A patent/AU2020302285A1/en not_active Abandoned
-
2021
- 2021-12-17 US US17/644,928 patent/US20220220175A1/en active Pending
- 2021-12-21 IL IL289200A patent/IL289200A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1658097B1 (en) | Nucleotide and cellular vaccine composition | |
| US9463228B2 (en) | Application of mRNA for use as a therapeutic against tumour diseases | |
| RU2526510C2 (ru) | Композиция для лечения рака легких, прежде всего, немелкоклеточного рака легких (нмкрл) | |
| JP5709264B2 (ja) | ワクチン組成物および方法 | |
| JPWO2008096831A1 (ja) | 癌の治療剤 | |
| JP2007523863A (ja) | 予防又は治療目的のためのmhcクラスi拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 | |
| JP2022538609A5 (cg-RX-API-DMAC7.html) | ||
| JP2022514116A5 (cg-RX-API-DMAC7.html) | ||
| JP2022539585A5 (cg-RX-API-DMAC7.html) | ||
| JP2022540396A5 (cg-RX-API-DMAC7.html) | ||
| CA2466530A1 (en) | Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell | |
| CN119770632A (zh) | 诱导免疫应答的组合物和方法 | |
| CN101146550A (zh) | 用于预防或治疗目的的激发、增强和维持对i类mhc-限制性表位的免疫应答的方法 | |
| KR101810840B1 (ko) | 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp) | |
| Zhang et al. | Recombinant cell-penetrating trichosanthin synergizes anti-PD-1 therapy in colorectal tumor | |
| US20260021184A1 (en) | Cancer Antigens and Methods | |
| WO2025224446A1 (en) | Novel cancer antigens and methods | |
| JP2023522193A5 (cg-RX-API-DMAC7.html) | ||
| WO2015005479A1 (ja) | 腫瘍抗原ペプチド | |
| Hersey et al. | Melanoma vaccines | |
| CN118843474A (zh) | 用于肺癌的治疗性rna | |
| CLONES | Genes Coding for Antigens Recognized on Human Tumors by Autologous Cytolytic T Lymphocytes zyxwvutsrqpon | |
| Class et al. | Patent application title: APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES Inventors: Ingmar Hoerr (Tubingen, DE) Florian Von Der MÜlbe (Stuttgart, DE) Florian Von Der MÜlbe (Stuttgart, DE) Steve Pascolo (Tubingen, DE) Steve Pascolo (Tubingen, DE) Assignees: CureVac AG | |
| Dummer | Vaccine therapy in advanced melanoma-State of the art | |
| HK1140961A (en) | Therapeutic agent for cancer |